Sanofi Names Montpellier Global Hub for Autoimmune Disease Research
Sanofi, in partnership with the Immun4Cure University Hospital Institute in Montpellier, has launched a Translational Centre of Excellence focused on developing treatments for autoimmune and inflammatory diseases. The centre aims to place patients at the core of R&D, spanning early research through advanced clinical trials.
Rheumatoid Arthritis | 16/10/2025 | By Dineshwori | 107
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
Rheumatoid Arthritis | 14/10/2025 | By Dineshwori
Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases
Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.
Rheumatoid Arthritis | 07/10/2025 | By Dineshwori | 161
Mochida Seeks Japan's Approval for Tocilizumab Biosimilar in Partnership with AYUMI
This application is based on the results of a Phase I clinical study conducted in Japan with 110 healthy adults and a Phase III clinical study conducted in Japan with 368 patients with rheumatoid arthritis.
Rheumatoid Arthritis | 28/03/2025 | By Abha | 467
Bio-Thera's BAT2506 Biosimilar to Simponi Gains EMA Review for EU Approval
The reference medicine golimumab has been approved in Europe for several indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
Rheumatoid Arthritis | 07/02/2025 | By Abha | 321
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy